Immatics (IMTX) Assets Average (2020 - 2026)
Immatics (IMTX) posted Assets Average of $630.4 million for Q4 2025, up 1.0% sequentially from $624.2 million in Q3 2025, and down 8.49% YoY from $688.9 million in Q4 2024.
Analysis
Immatics (IMTX) Assets Average (2020 - 2026) Analysis & Trends
Immatics has reported Assets Average for 6 years, with the latest figure at $630.4 million in Q4 2025.
- Quarterly Assets Average fell 8.49% year-over-year to $630.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $630.4 million (down 8.49% YoY) and the FY2025 annual result came in at $694.4 million, up 6.41% from the prior year.
- Assets Average advanced to $630.4 million in Q4 2025 per IMTX's latest filing, from $624.2 million in the prior quarter.
- Over five years, Assets Average peaked at $709.4 million in Q1 2025 and troughed at $217.2 million in Q4 2021.
- A 5-year average of $475.4 million and a median of $443.9 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2022: Assets Average tumbled 31.51% in 2021, then surged 78.03% in 2022.
- Over 5 years, Assets Average stood at $217.2 million in 2021, then soared by 78.03% to $386.7 million in 2022, then surged by 32.54% to $512.4 million in 2023, then soared by 34.44% to $688.9 million in 2024, then declined by 8.49% to $630.4 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $630.4 million, $624.2 million, and $658.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 600.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 600.31 Mn |
| Mar 31, 2026 | 645.30 Mn |
| Dec 31, 2025 | 630.40 Mn |
| Sep 30, 2025 | 624.19 Mn |
| Jun 30, 2025 | 658.57 Mn |
| Mar 31, 2025 | 709.44 Mn |
| Dec 31, 2024 | 688.91 Mn |
| Sep 30, 2024 | 654.55 Mn |
| Jun 30, 2024 | 692.35 Mn |
| Mar 31, 2024 | 629.11 Mn |
| Dec 31, 2023 | 512.45 Mn |
| Sep 30, 2023 | 461.43 Mn |
| Jun 30, 2023 | 426.46 Mn |
| Mar 31, 2023 | 411.16 Mn |
| Dec 31, 2022 | 386.65 Mn |
| Sep 30, 2022 | 375.11 Mn |
| Jun 30, 2022 | 354.85 Mn |
| Mar 31, 2022 | 258.25 Mn |
| Dec 31, 2021 | 217.18 Mn |
| Sep 30, 2021 | 247.65 Mn |